Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Receivables (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Receivables for 6 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 12347.62% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 225.57% increase, with the full-year FY2024 number at -$1.2 million, up 76.54% from a year prior.
  • Change in Receivables was $2.6 million for Q3 2025 at Maxcyte, up from $238000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $4.0 million in Q4 2022 to a low of -$3.4 million in Q1 2023.
  • A 5-year average of $182689.5 and a median of $238000.0 in 2025 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 46455.56% in 2023; the steepest drop was 294.14% in 2023.
  • Maxcyte's Change in Receivables stood at $918900.0 in 2021, then skyrocketed by 336.63% to $4.0 million in 2022, then plummeted by 141.25% to -$1.7 million in 2023, then soared by 107.37% to $122000.0 in 2024, then skyrocketed by 2008.2% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Change in Receivables are $2.6 million (Q3 2025), $238000.0 (Q2 2025), and $839000.0 (Q1 2025).